Luye Pharma is a China-headquartered fully integrated oncology and CNS specialist. Bruno Delie, general manager for Switzerland, discusses the organization’s ambitious European expansion plan, looking to establish affiliates in the top five markets within the continent in order to introduce four or five new products from their pipeline in the next five years. Moreover, he explains how Luye developed its footprint in Europe after the acquisition of Acino’s transdermal patch and implant business unit.
We want to go from a business-to-business (B2B) model ... to a business-to-consumer (B2C) specialty pharma model by having our own sales organization in key European markets
